Is Selling All-time Stock Like Clementia Pharmaceuticals Inc. (CMTA) a Winning Strategy?

February 15, 2018 - By simple simple

The stock of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) reached all time low today, Feb, 15 and still has $11.64 target or 3.00 % below today’s $12.00 share price. This indicates more downside for the $380.61M company. This technical setup was reported by If the $11.64 PT is reached, the company will be worth $11.42 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 1.72% or $0.21 during the last trading session, reaching $12. About 137,784 shares traded or 114.58% up from the average. Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

More notable recent Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) news were published by: which released: “Clementia Pharmaceuticals Readies $100 Million IPO” on July 31, 2017, also with their article: “Clementia Announces Closing of Over-Allotment Option in its Initial Public …” published on August 21, 2017, published: “Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors” on January 31, 2018. More interesting news about Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) were released by: and their article: “Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A …” published on January 09, 2014 as well as‘s news article titled: “Clementia Pharmaceuticals Raises US $60 Million in Mezzanine Financing to …” with publication date: June 23, 2015.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $380.61 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.